Nabilone for Agitation Blinded Intervention Trial

PHASE3RecruitingINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Alzheimer DiseaseAgitation
Interventions
DRUG

Nabilone

After the screening period, participants randomized to the nabilone arm will receive nabilone for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.

OTHER

Placebo

After the screening period, participants randomized to the placebo arm will receive placebo capsules for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.

Trial Locations (6)

T2N 4N1

RECRUITING

University of Calgary, Calgary

N6A 5W9

RECRUITING

London Health Sciences Centre, London

M4N 3M5

RECRUITING

Sunnybrook Health Sciences Centre, Toronto

Unknown

RECRUITING

Centre for Addiction and Mental Health, Toronto

RECRUITING

St. Michael's Hospital, Toronto

L1N 5S9

RECRUITING

Ontario Shores Centre for Mental Health Sciences, Whitby

All Listed Sponsors
collaborator

Alzheimer's Drug Discovery Foundation

OTHER

lead

Sunnybrook Health Sciences Centre

OTHER

NCT04516057 - Nabilone for Agitation Blinded Intervention Trial | Biotech Hunter | Biotech Hunter